Slides Available from CCTST Grand Rounds March 24
Andrew Mulberg, MD, Vice President of Global Regulatory Affairs for Amicus Therapeutics, discussed FDA from a Former FDAer: Secrets and insights into regulatory review and drug development, especially as they relate to precision medicine and rare diseases. Mulberg is a former deputy director of the FDA.
Mulberg also spoke on First in Human Trials and Safety Assessment for Rare and Orphan Diseases at the March 23-24 conference Ethics of Integrating Research and Clinical Care at Cincinnati Children's.
Become a Member